You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1821526 |
---|---|
Category | Antibodies |
Description | Nerve growth factor Antibody |
Species/Host | Mouse |
Clonality | Monoclonal |
Clone Number | mab 911 |
Tested applications | Blocking, Crystallography, ELISA, In vitro, In vivo, NeA |
Reactivity | Human, Mouse |
Isotype | IgG1 |
Concentration | 1 mg/ml |
Conjugation | Unconjugated |
Target | Nerve growth factor |
UniProt ID | P01138 |
Storage | Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C. |
Buffer/Preservatives | PBS with 0.02% Proclin 300. |
Alternative names | Beta-nerve growth factor; Beta-NGF Read more... |
Note | For research use only |
Application notes | The specificity of the original format of the antibody to NGF was confirmed by ELISA analysis (EC50 = 0.37 nM). The antibody was evaluated for its ability to block the binding of hNGF to the TrkA and p75 NGF receptors in various in vitro assays, such as blocking of TrkA autophosphorylation and blocking of NGF-dependent survival of dorsal root ganglion sensory neurons. The antibody was a potent blocker of all activities (Hongo et al., 2000; PMID: 10952410). In vivo administration of the antibody significantly reduces bone cancer pain behaviors (Sevcik et al., 2005; PMID: 15836976 and Halvorson et al., 2005; PMID: 16230406 and Buehlmann et al., 2019; PMID: 30161041) and fracture pain-related behaviors (Koewler et al., 2007; PMID: 17638576). The structure of Nerve Growth factor in complex with the Fab fragment was determined. Library Scanning Mutagenesis method was used to convert the original antibody in the humanized antibody tanezumab. The antibody bound human and murine NGF with high affinity (KD ~10 nM). Tanezumab and the original antibody blocked both TrkA and p75NTR binding to NGF and inhibited NGF-dependent neuron survival. Tanezumab inhibited NGFdependent survival with an IC50 of 15 pM; under the same conditions, 911 inhibited NGF with an IC50 of 400 pM (La Porte et al., 2014; PMID: 24830649). Preventative and therapeutic treatment with the antibody significantly prevented, or reversed, MIA-induced pain behaviour in osteoarthritis (Xu et al., 2016; PMID: 27208420). |
Expiration Date | 12 months from date of receipt. |
ELISA, IHC-P, WB | |
Human, Mouse, Porcine, Rat | |
Rabbit | |
Polyclonal | |
Unconjugated |
ELISA, IF, IHC, WB | |
Human, Mouse | |
Rabbit | |
Polyclonal | |
Unconjugated |
Filter by Rating